William C. Bertrand Jr.
CIK: 0001291937
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 16, 2026ARDX
ARDELYX, INC.
Award(A)Direct12.3K shares- - Jun 16, 2026ARDX
ARDELYX, INC.
Award(A)Direct26.5K shares- - Aug 28, 2025ADAP
Adaptimmune Therapeutics PLC
Sale(S)Direct207K shares at avg. $0.01$2K - Jun 18, 2025ARDX
ARDELYX, INC.
Award(A)Direct19.4K shares- - Jun 18, 2025ARDX
ARDELYX, INC.
Award(A)Direct41.6K shares- - Feb 20, 2025ADAP
Adaptimmune Therapeutics PLC
Award(A)DirectOption to purchase Ordinary Shares
1.1M shares- - Feb 20, 2025ADAP
Adaptimmune Therapeutics PLC
Award(A)DirectOption to purchase Ordinary Shares
1.6M shares- - Jan 17, 2025ADAP
Adaptimmune Therapeutics PLC
Sale(S)Direct5.6K shares at avg. $0.58$3K - Jan 15, 2025ADAP
Adaptimmune Therapeutics PLC
Sale(S)Direct9.8K shares at avg. $0.57$6K - Jan 13, 2025ADAP
Adaptimmune Therapeutics PLC
Sale(S)Direct5.5K shares at avg. $0.59$3K - Jan 13, 2025ADAP
Adaptimmune Therapeutics PLC
Sale(S)Direct4.3K shares at avg. $0.59$3K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  ARDX ARDELYX, INC. | Award(A) | 12,345 | - | $0 | Direct |
| Jun 16, 2026 | ARDX ARDELYX, INC. | Award(A) | 26,455 | - | $0 | Direct |
| Aug 28, 2025 |  ADAP Adaptimmune Therapeutics PLC | Sale(S) | 207,000 | $0.01 | $2,091 | Direct |
| Jun 18, 2025 | ARDX ARDELYX, INC. | Award(A) | 19,390 | - | - | Direct |
| Jun 18, 2025 | ARDX ARDELYX, INC. | Award(A) | 41,551 | - | - | Direct |
| Feb 20, 2025 | ADAP Adaptimmune Therapeutics PLC | Award(A) Option to purchase Ordinary Shares | 1,074,696 | - | - | Direct |
| Feb 20, 2025 | ADAP Adaptimmune Therapeutics PLC | Award(A) Option to purchase Ordinary Shares | 1,612,032 | - | - | Direct |
| Jan 17, 2025 | ADAP Adaptimmune Therapeutics PLC | Sale(S) | 5,584 | $0.58 | $3,243 | Direct |
| Jan 15, 2025 | ADAP Adaptimmune Therapeutics PLC | Sale(S) | 9,803 | $0.57 | $5,635 | Direct |
| Jan 13, 2025 | ADAP Adaptimmune Therapeutics PLC | Sale(S) | 5,471 | $0.59 | $3,216 | Direct |
| Jan 13, 2025 | ADAP Adaptimmune Therapeutics PLC | Sale(S) | 4,268 | $0.59 | $2,509 | Direct |
1-11 of 11 transactions
About Bertrand William C JR
Bertrand William C JR (SEC CIK 0001291937) files insider reports with the SEC as Director of ARDELYX, INC. (ARDX) and Chief Operating Officer of Adaptimmune Therapeutics PLC (ADAP).
Signal8 holds 6 ownership filings by Bertrand William C JR, all Form 4s, filed between Jan 15, 2025 and Jun 18, 2026. Those filings report 11 transactions, from Jan 13, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bertrand William C JR's filings is in WALTHAM, MA.
Recent filings by Bertrand William C JR
- Jun 16, 2026: Grants or awards of ARDX shares (2 lines, Form 4, code A).
- Aug 28, 2025: Open-market sale of ADAP shares (Form 4, code S).
- Jun 18, 2025: Grants or awards of ARDX shares (2 lines, Form 4, code A).
- Feb 20, 2025: Grants or awards of ADAP derivative securities (2 lines, Form 4, code A).
- Jan 17, 2025: Open-market sale of ADAP shares (Form 4, code S).
Other insiders filing for ARDELYX, INC. (ARDX)
- Hohenleitner Susan, Chief Financial Officer
- Reilly Joseph James
- Bishop John E
- Brady James Parker, Chief Human Resources Officer
- Foster Eric Duane, Chief Commercial Officer
- Kelliher Mike, Chief Business Officer